Help shape GoConqr. What should we add next?

Flashcards

Biochem 2

Alexander Wolff English 150 cards

diagram to demonstrate the role of HMGCoA reductase and the action of statins

Cards in this deck (150)

  1. 1diagram to demonstrate the role of HMGCoA reductase and the action of statinsdiagram to demonstrate the role of HMGCoA reductase and the action of statins
  2. 2name treatments for hyper lipidaemia- lifestyle - everyone
    - patients at high risk- those with clinical disease in any vascular bed (cerebral, coronary, peripheral) should be given secondary prevention
    -primary prevention to those with genetic hyperlipiademia/ high calculated CHD risk/ diabetes and age > 40
  3. 3what association has been noted , in JAMA cardiology 2017, relating to intensity of statin use and one year mortality meta-analyses have shown that increasing beyond certain intensity may not yield net benefitincreased intensity decreases one year mortalitywhat association has been noted , in JAMA cardiology 2017, relating to intensity of statin use and one year mortality meta-analyses have ...
  4. 4how might we analyse atheroma regression with treatments?- intravascular ultrasoundhow might we analyse atheroma regression with treatments?
  5. 5look at this in your own timelook at this in your own time
  6. 6how do hepatocytes clear LDL?- LDL attaches to LDLR on hepatocyte membrane
    - endocytosis of particle
    - coated in clarithrin ( vesicle is coated)
    - transported as an endosome
    - lysozyme break-down into lysosome
    - synthesis of LDLR by nucleus
    - LDLR recycled by endosome
  7. 7shownshown
  8. 8how then, does PCSK9 work?- is produced in the nucleus of the hepatocyte (PCSK9 gene)
    - attaches to LDL- LDLR complex
    - prevents LDLR recycle at endosome-> therefore less LDLR at the membrane
    -therefore increased circulating LDL not being metabolised
  9. 9imageimage
  10. 10genetic studies have shown loss of function mutations of the PCSK9 to do what to CHD risk?- reduced risk
    - PCSK9 cannot prevent LDLR recycle - therefore more LDL uptaken and metabolised
    data demonstrated in black subjects
  11. 11how then, might we utilise this for our benefit?- mimic the loss of function alleles by producing Mabs against PCSK9
    more LDLR, less LDL
    - EVOLOCUMAB a great example
    'vaccine against PCSK9 lowers cholesterol in mice"
  12. 12give some side-effects of statins- rhabdomyolysis, myalgia - don't use statins if symptoms exist (may be look at CK)
    - liver- LFTs once per month according to NICE- ALT 2-3x higher than normal common and acceptable. Review if >3 x greater- make sure you know statins not always the cause
    - diabetes- risk increased by 9%- earlier presentation/ those who wouldn't have gotten it
    CVD benefit outweigh the risks
  13. 13what are the target cholesterol levels - LDL? - Non-HDL?- <4
    - LDL <2
    Non-HDL <2.5
  14. 14how much protein exists in the serum in total ?- 60-80 g/L total serum protein
    albumin makes up a large bulk- 35-50 g/L
    -globulins 22-36g/L
  15. 15name some functions of serum proteins- transport
    -immunity
    - oncotic pressure
    - hormones
    - clotting
    - enzymes
    - lipoproteins
  16. 16name some lab tests used to measure the quantity of serum proteinalbumin- LFT profile and bone profile
    total protein- LFT profile
    GLOBULINS= TP- albumin (found in LFT profile)
    can get specific protein: CRP, haptoglobin, caeruloplasmin (copper carriage-Wilsons?)
    - complement, transferrin, beta-2-microglobulin
    serum protein electrophoresis as a diagnostic test
  17. 17describe albumin- synthesised by the liver
    - half life of approximately 20 days
    - serum concentration dependent on: synthesis, breakdown, loss and fluid status
  18. 18what are the main functions of albumin?- for transport
    - provides oncotic pressure
  19. 19name causes of low albumin- reduced synthesis
    - increased breakdown
    - increased losses- renal
    - dilution (including artefact)
    - redistribution
  20. 20name causes of high albumin - these are rare- standing
    - dehydration
    - venous stasis
  21. 21hypoalbuminaemia caused by reduced synthesis is caused how?- chronic liver disease- liver produces albumin until 90-95% damage
    - malnutrition and malabsorption- reduced supply of AA from GIT to liver
  22. 22hypoalbuminaemia caused by increased catabolism is caused how?- severe illnesses
    e.g. : sepsis, inflammation, trauma, malignancy
    related to a poor prognosis (esp. malignancy)
  23. 23hypoalbuminaemia caused by increased excess losses is caused how?- renal - nephrotic syndrome: proteinuria >3g/24hr
    - results in low albumin plus oedema (oncotic pressure changes),
    - dyslipidaemia, viscosity and renal impairment other causes
    - GI- protein losing enteropathy
    Skin- Burns, Psoriasis
  24. 24diagram to explain why absence of a colloid pressure from albumin results in oedema. Not able to provide adequate pressure for fluid in extravascular compartment to reabsorb into distal capillary and so is left in interstitiumdiagram to explain why absence of a colloid pressure from albumin results in oedema. Not able to provide adequate pressure for fluid in e...
  25. 25hypoalbuminaemia caused by haemodilution excess losses is caused how?iatrogenically- excess fluid
    - oedema- CCF, CLD
    - pregnancy
    - sample contamination
  26. 26case of a 57 year old male with advanced alcoholic liver disease - has a microcytic anaemia key to look into historycase of a 57 year old male with advanced alcoholic liver disease - has a microcytic anaemia key to look into history
  27. 2778 year old woman with SOB/infected leg ulcers - CRP suggests that the infection not to blame - - Hb low- due to dilution - would need other tests to confirm CCF- but key is to know that reduced Hb could be suggestive of a dilutional hypoalb78 year old woman with SOB/infected leg ulcers - CRP suggests that the infection not to blame - - Hb low- due to dilution - would need ot...
  28. 28describe redistribution as a cause of hypoalbuminaemia- common cause of acute change
    - redistribution from plasma to interstitial
    - increased capillary permeability (sepsis, inflammation, response to trauma)
    - recumbency- small but significant changes
  29. 2956 year old acute infective pancreatitis- albumin low (redistribution due to sepsis)56 year old acute infective pancreatitis- albumin low (redistribution due to sepsis)
  30. 30describe the consequences of hypoalbuminaemia- reduced oncotic pressure - oedema
    - reduced binding capacity a) transport b) potential for increased drug activity (less bound- more bioavailability)
  31. 31describe oncotic pressure fully- osmotic pressure due to colloids (proteins)
    - opposes hydrostatic pressure
    - albumin major component
    - acts to hold fluid within the circulating volume
  32. 32diagramdiagram
  33. 33how does this progress to oedema ?- fluid leaks out of capillaries into the interstitium
  34. 34describe how hypoalbuminaemia causes changes to calcium levels- albumin binds calcium- around 50% - not physiologically active
    - physiologically active calcium is free or ionised
    - free calcium homeostasis is tightly controlled
    - hypoalbuminaemia reduces total calcium but not free calcium
    - lab needs to adjust for this pseudohypocalcaemia
  35. 35example of how we adjust for albuminexample of how we adjust for albumin
  36. 36how might drugs be affected by hypoalbumaenia ?- drugs compete for albumin binding sites
    - no biological feedback
    - risk of toxicity at apparently normal drug levels in the presence of hypoalbuminaemia
    - might necessitate the use of an adjusted drug level
  37. 37how might we simply measure proteinuria ?- dipstick
  38. 38quantify normal proteinuria- normal urine total protein < 150mg/24hr
    - normal albumin urine <30 mg/24hr
  39. 39to what sensitivity can protein dip-sticks measure albumin?- albumin > 300mg/L
    not very
  40. 40describe simple limitations of urine dipsticks- bacterial contamination
    - disinfectant
    - very concentrated sample
    - haematuria
    - bodily secretions
    - errors in reading strips
  41. 41describe the albumin:creatinine ratio (ACR) and what is is used for- screening tool for renal disease etc
    - is a spot urine test in the early morning (fresh in the morning)
    - used as a marker of renal disease and a marker for CVD morbidity and mortality
    normal ACR <3g/mol
  42. 42an ACR of 3- 30g/mol is clinically what?- microalbuminaemia
  43. 43an ACR of 30- 70g/mol is clinically what?proteinuria
  44. 44an ACR of 70-250g/mol is clinically what?proteinuria
  45. 45an ACR of >250g/mol is clinically what?nephrotic
  46. 46table in summarytable in summary
  47. 47name the four causes of proteinuria- glomerular
    - tubular
    - post-renal
    - overflow
  48. 48describe the glomerular cause to proteinuria- most common pathological cause
    - increased permeability of the BASEMENT MEMBRANE
    - nephrotic syndrome - >3g/24hr, v low serum alb, most commonly immunologically mediated GLOMERULONEPHRITIS
    - can happen transiently through illness or exercise
  49. 49name post renal causes of proteinuria- urinary tract infection
    - semen
    pus
    blood
    contamination
    - post-renal tumour (urothelial?)
  50. 50describe overflow as a cause of proteinuriaincreased plasma concentration of protein
    - filtered load exceeds reabsorptive capacity
  51. 51describe tubular causes of proteinuria- impaired reabsorption of protein (back into blood, from the tubules)
    - causes: heavy metals, nephrotoxic drugs (NSAIDs etc- find more), chronic pyelonephritis, inherited syndromes such as fanconi syndrome - inadequate reabsorption at the proximal nephron
  52. 52how might protein in fluid be useful in determining the type of fluid?- transudates exist with LOW PROTEIN and are a result of filtration across the capillary endothelium (oncotic pressure)
    - exudates are fluids with HIGH PROTEIN and result from inflammatory processes that increase permeability
    therefore differentiate the cause
  53. 53how do we work out if the fluid is exudate or transudate?- by measuring albumin in the serum and in the fluid
    - Light et al. 1972.
    - fluid albumin:serum albumin > 0.5 THEN THE FLUID IS AN EXUDATE
  54. 54what is CSF?- cerebrospinal fluid
    - is an ultra filtrate of plasma
    normally has low protein content (0.1-0.4 g/L)
  55. 55elevated protein in the CSF could be due to?- may be pathological-
    infection
    chronic inflammation
    blockage in spinal canal- tumour, fracture
    - contamination from blood is common in sampling (LP)- traumatic tap/ SAH
  56. 56a finding of hypergammaglobulinaemia is found to be poly/mono clonal how?- serum protein electrophoresis
    - polyclonal - inflammation, infection, autoimmune disease, CLD
    - mono-clonal- stem from an identical immune cell
  57. 57name causes of a monoclonal hypergammaglobulinaemia- multiple myeloma- stem from a single immune cell
    - Waldenström's macroglobulinaemia
    - MGUS
    - other b-cell malignancies
  58. 58natural immunity refers to ?- the acute phase response
  59. 59name +ve acute phase proteins- CRP
    -ferritin
    - alpha-1-antitrypsin
    - caeruloplasmin
    - fibrinogen
    - haptoglobin
    - serum amyloid A
  60. 60name -ve acute phase proteins- albumin
    - transferrin
  61. 61describe CRP as a marker of inflammation- NON-SPECIFIC, very sensitive acute phase marker of inflammation
    - rise after 6-12 hours
    peak at 48 hours
    - 10000x increase
    - half life of around 19 hours- rapid clearance
  62. 62discuss CRP in viral/bacterial infection- normal CRP does not rule out inflammation- not specific
    bacterial infection >40mg/L usually vs >300mg/L in sepsis
    - viral infection- only minor elevation
    - fall approx. 50% in 24 hours if antibiotics successful
  63. 63in what cases then, should we use CRP?- detecting infection- BACTERIAL/ immunosuppression
    - response to treatment
    - connective tissue disease (NOT SLE- ESR)
    - IBD
    - prognosis e.g. acute pancreatitis
    - cardiovascular risk (high sensitivity CRP)
  64. 64describe alpha-1-antitrypsin- inhibitor of neutrophil elastase
    - normally controls proteolytic enzymes from macrophages
    - deficiency autosomal co-dominant
    - homozygotes 1/4000
    - linked with early onset EMPHYSEMA and CLD
  65. 65describe haptoglobin- binds free Hb released from intravascular haemolytic
    - taken up by reticuloendothelial system
    prevents loss of iron
    - low in haemolytic anaemia (sickle cell disease) but also CLD, mets, sepsis
  66. 66describe caeruloplasmin- functions to oxidoreductase and iron transport
    - copper carrying capacity
    - low in Wilson's disease
    - increased in acute phase
    and in pregnancy, OCP
  67. 67quick definition of metabolism- all chemical reactions taking place in the body which generate transfer of use energy
  68. 68describe inherited metabolic disorders (IMD)inherited genetic abnormalities
    - absence or malfunction of an enzyme system
    - individually rare but collectively make up 1in 3-4000 births
  69. 69what must you remember about IMDs?- they are diverse in presentation and often multisystem
  70. 70describe the pathophysiology of IMDsdescribe the pathophysiology of IMDs
  71. 71describe how the pathophysiology may cause symptoms in IMD- accumulation of substrate
    - deficient product
    - secondary metabolic phenomena
  72. 72what is the incidence of phenylketonuria ?- 1 in 10,000
  73. 73what mutations are responsible for phenylketonuria ?- to the phenylalanine hydroxylase gene
    - leads to absent or reduced enzymatic activity or impaired binding to cofactor BH4
  74. 74how do we diagnose phenylketonuria?- seeing increased plasma phenylalanine (build up of substrate)
    - seeing reduced tyrosine (product)
  75. 75how might this influence the person affected by PKU?- neurotoxicity from PA
    - impaired neurotransmitter synthesis
    - developmental/mental problems, seizures and behavioural problems
    mental retardation
  76. 76what treatment exists for phenylketonuria?- low PA diet (reduces neurotoxicity)
    - supplements (tyrosine)
    prognosis is good in this instance
  77. 77chemical schematic of PKUchemical schematic of PKU
  78. 78how might we classify IMDs?- 1. disorders involving complex molecules
    2. intoxication
    3. energy insufficiency
  79. 79describe the typical IMD that is due to presence of complex molecules- permanent
    - progressive
    - independent of intercurrent illnesses
    -unrelated to food intake
  80. 80what is the pathophysiology of this class (complex molecules)?- cellular organelles involved
    - diseases that disturb the synthesis or catabolism of complex molecules
  81. 81give examples of IMDs involving complex molecules- lysosomal storage disorders
    - peroxismal disorders - x-linked adrenoleukodystrophy, Zellwegers
    - congenital disorders of glycosylation
  82. 82describe a presentation of a patient with a lysosomal storage disorder- repeated URTI
    - dysmorphism
    - developmental delay
    - behavioural problems such as aggressive behaviour
    - enlarged abdomen
  83. 83what might you find on examination in a patient with a lysosomal storage disorder?- macrocephaly
    - course facial features
    - kyphosis
    - hepatosplenomegaly
    - claw hands
    - umbilical hernia
  84. 84typical appearance of a patient with lysosomal storage disorder findings consistent with a mucopolysaccharidosistypical appearance of a patient with lysosomal storage disorder findings consistent with a mucopolysaccharidosis
  85. 85describe the function of a lysosome- is a cell recycling centre
    - 40 now identified
  86. 86how do lysosomal storage disorders work?- accumulation of partially degraded substances
    - within the lysosome
    - leads to disturbed cell homeostasis and early cell death
  87. 87which cells are most likely to become damaged in a lysosome storage disorder?- ones with low-turnovers- neurons
    - or rich in lysosomes- such as white cells
  88. 88list clinical features of a lysosome storage disorder- 3-6 months of age
    -neurological symptoms
    - hepatosplenomegaly
    - resp/ cardiac problems
    might be bony abnormality
  89. 89what is the natural course of LSD?- slow progression to life- threatening multi-organ disease
  90. 90how do we classify LSDs?by the storage material affected
    e.g. mucopolysaccharidosis oligosaccharidoses, sphingolipidosis
  91. 91what material accumulates in mucopolysaccharidosis?- glucosaminoglycans
    examples of conditions- Hurler, Scheie, Hunter, Sanfilipo
  92. 92what material accumulates in oligosaccharidoses?oligosaccharides
    - fucosidosis
    mannosidosis
    sialidosis
    schindlers disease
  93. 93table to summarisetable to summarise
  94. 94what investigation findings might be found in a patient with a mucopolysaccharidosis (LSD)- haematology/biochem normal
    - urine MPS gives positive glucosaminoglycans
    increased dermatan sulphate and heparan sulphate
  95. 95which cells might need analysing in the case of mucopolysaccharidosis?- white cells
  96. 96give treatment options for LSD- supportive and palliative care
    - ENZYME replacement therapy
    - bone marrow transplantation
    - substrate reduction therapy
    - chaperone therapy/gene therapy
  97. 97name an enzyme replacement drug used in LSD- elaprase
  98. 98name members of the MDT for LSD- paeds, cardiac, ortho, ent, neuro, psych, physio
  99. 99what is the general consensus on enzyme replacement therapy for LSDseems to largely improve symptoms and there is improved quality of life
    -
    - long term unsure
  100. 100Mucopolysaccharidosis (MPS) leads to the abnormal build up of?heparan sulphate
    - dermatan sulphate
    - keratan sulphate =
  101. 101define an intoxication IMD- symptoms due to acute or progressive intoxication from the accumulation of toxic compounds proximal to a metabolic block
  102. 102what kind of presentations can occur with an intoxication IMD?- acute- vomiting, lethargy, coma, liver failure
    chronic- progressive developmental delay, cardiomyopathy
  103. 103give examples of intoxication IMDs- urea cycle defects
    -metal metabolism disorders such as Wilson's disease
    -PKU, tyrosinaemia- aminoacidurias
    - organic acidurias- methylmalonic aciduria
    - sugar intolerance (galactosaemia)
  104. 104give a typical presentation for a person with a urea cycle defect- infant
    - fitting/seizures
    very high NH3 (ammonia)-
  105. 105how is ammonia produced ?- catabolism of amino acids
  106. 106how can we define hyperammonaemia?- premature neonate NH3 > 150 umol/L
    -term neonate > 100 umol/L
    -infan, child and adult >40 umol/L
  107. 107give symptoms of hyperammonaemia- acute tachypnoea
    - lethargy
    - vomiting convulsions
    - encephalopathy
    need to promptly investigate to avoid irreversible neurological damage
  108. 108ammonia detoxification- learn this really wellammonia detoxification- learn this really well
  109. 109what is the commonest inherited defect of the urea cycle ?- OTC deficiency - refer to urea cycle
  110. 110name other IMDs that might cause an increased ammonia- organic acidurias - e.g. methylmalonic acuduria
    - fatty acid oxidation defects
    - hyperornithinaemia, hyperammonaemia, homocitrillinuaemia (HHH syndrome)
  111. 111case from lecturecase from lecture
  112. 112these results from the case are consistent with which urea cycle defect?- carbamyl phosphate synthase deficiency (CPS-1)
    - reduced citrilline production at the same time as raised ammonia - less conversion from NH3 to cit
    these results from the case are consistent with which urea cycle defect?
  113. 113how would we acutely manage this patient ?- want to reduce intoxication by NH3- therefore stop protein intake
    - high calorie infusion (glucose) to prevent catabolism (breakdown of protein)
    - arginine - to drive urea cycle
    - promote ammonia removal - sodium benzoate/pheynlbutyrate / haemofiltration if NH3 >300 umol/L
  114. 114what management should be given long-term for this patient? remember that even after this significant developmental delay will be witnessed- referred to paediatric metabolic clinic for long-term follow up
    - low protein diet
    - benzoate and phenylbutryate
    -arginine (drive) and citrulline
    - emergency regime to avoid catabolism during intercurrent illness
  115. 115what sites are used for the urea cycle?-liver- mainly
    kidney- lesser extent
    - this is in the mitochondria of the respective organs
  116. 116what then, might be the natural course for a patient with a urea cycle deficiency ?- liver transplant
  117. 117define IMDs that cause impaired energy metabolism- symptoms due to deficiency in liver, metabolism, myocardium and muscle/brain
  118. 118give common symptoms of impaired energy metabolism IMDs- hypoglycaemia
    - hyperlactiacidaemia
    - hypotonia
    - myopathy
    - cardiomyopathy
    -SUDIs- sudden unexpected death in infancy
  119. 119give examples of the above- fatty acid oxidation defects
    - glygenoses
    - gluconeogenesis defects
    - mitochondrial respiratory chain disorders
  120. 120history of case 3history of case 3
  121. 121results from investigations note hypoglycaemia raised ALT- related to liver damageresults from investigations note hypoglycaemia raised ALT- related to liver damage
  122. 122how does the body respond to fasting?- through glycogenolysis / gluconeogenesis- glycogen break down in the muscle/glucose production in the liver from fatty acids and lactate
    - through reduced peripheral glucose utilisation - namely by utilising other energy substrates such as fatty acids and ketones (oxidation)
  123. 123—
  124. 124what blood glucose level defines a hypoglycaemia ?- <= 2.6mmol/L
  125. 125how may a neonate/infant present in the case of hypoglycaemia?- irritability
    - somnolence- sleepiness/drowsiness
    - tachypnoea
    - hypothermia
    - apnoea
    - hypotonia
    - seizures
  126. 126how might older infants /children/adults present with hypoglycaemia ?- sweating
    -apathy
    - nausea
    - headaches
    - unusual behaviour
    - seizures
    - coma
  127. 127give metabolic causes of hypoglycaemia- disorders of fatty acid oxidation - production of acylcarnitines such as octanoylcarnitine
    - disorders of carbohydrate metabolism
    - disorders of organic metabolism
    - disorders of gluconeogenesis
  128. 128urine organic acids such as ketones and a blood spot acylcarnitines is consistent with a diagnosis of?- medium-chain acyl COA dehydrogenase deficiency (MCADD)
  129. 129at what age does a case of MCADD tend to present?- usually 4 months to 3 years
  130. 130discuss MCADD- incidence of 1:8000
    - metabolic crisis precipitated by fasting, illness, operations
    - first crisis fatal in up to 25%
    - occasionally asymptomatic
  131. 131how then, is MCADD diagnosed?- organic acids
    -acylcarnitines- increased octonoyl carnitine
    -mutation analysis - common mutation = c.985A>G (K329E)
  132. 132describe the acute management of MCADD- acute - high dose glucose IV +- insulin
    - IV cartinine
  133. 133describe the chronic management of MCADD- avoid fasting (avoidance of fat breakdown)
    - diet low in fat and high in carb (utilising glucose instead of fat)
    - emergency regime
    - oral carnitine if deficient
  134. 134case 3 summary of managementcase 3 summary of management
  135. 135when should you consider IMD?- in any child with: neurological deterioration/metabolic acidosis/hypoglycaemia/hypotonia/cardiomyopathy/liver dysfunction/dysmorphism/SUDI
  136. 136what blood tests would be performed if suspected inborn errors in metabolism are suspected?- glucose
    - ammonia
    - free fatty acids and 3 hydroxybutyrate
    - blood gases
    -lactate
    - amino acids
    - acylcarnitines
    -LFTs (deranged?)
    - FBC
  137. 137what specific urine test would be useful for diagnosing IEM?- reducing substances
    - ketones
    - organic acids
    - amino acids
  138. 138name specific diagnostic tests for IEM- mucopolysaccharide test/screen
    - very long chain fatty acids- for peroxisomal disorders
    - CSF analysis (lactate respiratory chain disorders)
  139. 139name non biochemical tests for the diagnosis of IEM- neuro-imaging (MRI peroxisomal disorders- white matter changes)
    - ophthalmology assessment- cataracts galactosaemia
  140. 140name confirmatory tests for the diagnosis of IEM- functional studies
    - enzyme studies
    - mutation analysis
  141. 141name family tests for IEM- sibling testing
    - prenatal diagnosis
    newborn screening
  142. 142slide - important to know these screening belowslide - important to know these screening below
  143. 143—
  144. 144from when were newborn blood sport screening tests available for things like sickle, CF and MCADD?- 2004-2008
  145. 145name three amino acid disorders now screened for in the UK- PKU
    - maple syrup urine disease
    - homocystinuria
  146. 146name the fatty acid oxidation disorder screened for in the UK- MCADD
  147. 147name the two organic acidurias now tested for/screened for in the UK- isovaleric acuduria
    - Glutaric acuduria type 1 (GA1)
  148. 148name the other three screened for diseases that make up the NHS England newborn blood spot screening programme (all of the above also involved)- Sickle cell
    - CF
    - congenital hypothyroidism
  149. 149when is the newborn screened in these instances?- 5-8 days old blood spot
  150. 150—

Information

Description
Flashcards on Biochem 2, created by Alexander Wolff on 17/02/2018.
Created by
Alexander Wolff
Views
4
Rating

Feedback

What is it about?

What should we add next?